Persistence and adherence with mirabegron versus antimuscarinics in overactive bladder: retrospective analysis of a UK General Practice Prescription Database

被引：0
|
作者：
Wagg, Adrian [1 ]
Foley, Steve [2 ]
Peters, John [3 ]
Nazir, Jameel [4 ]
Kool-Houweling, Leanne [5 ]
Scrine, Ludmila [6 ]
机构：
[1] Univ Alberta, Med, Edmonton, AB, Canada
[2] Royal Berkshire Hosp, Dept Urol, Reading, Berks, England
[3] Barts Hlth NHS Trust, Whipps Cross Hosp, Dept Urol, London, England
[4] Astellas Pharma Europe Ltd, Hlth Econ & Outcomes Res, Chertsey, England
[5] Quintiles Advisory Serv, Hoofddorp, Netherlands
[6] Astellas Pharma Europe, Chertsey, England
来源：
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY | 2017年 / 211卷
关键词：
D O I：
10.1016/j.ejogrb.2017.01.028
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
2
引用
收藏
页码：199 / 200
页数：2
相关论文
共 50 条
  • [1] Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database
    Wagg, Adrian S.
    Foley, Steve
    Peters, John
    Nazir, Jameel
    Kool-Houweling, Leanne
    Scrine, Ludmila
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2017, 71 (10)
  • [2] A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
    Jameel Nazir
    Zalmai Hakimi
    Florent Guelfucci
    Amine Khemiri
    Francis Fatoye
    Ana María Mora Blázquez
    Marta Hernández González
    BMC Urology, 18
  • [3] A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
    Nazir, Jameel
    Hakimi, Zalmai
    Guelfucci, Florent
    Khemiri, Amine
    Fatoye, Francis
    Blazquez, Ana Maria Mora
    Gonzalez, Marta Hernandez
    BMC UROLOGY, 2018, 18
  • [4] Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice
    Chapple, Christopher R.
    Nazir, Jameel
    Hakimi, Zalmai
    Bowditch, Sally
    Fatoye, Francis
    Guelfucci, Florent
    Khemiri, Amine
    Siddiqui, Emad
    Wagg, Adrian
    EUROPEAN UROLOGY, 2017, 72 (03) : 389 - 399
  • [5] Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
    Nazir J.
    Berling M.
    McCrea C.
    Fatoye F.
    Bowditch S.
    Hakimi Z.
    Wagg A.
    PharmacoEconomics - Open, 2017, 1 (1) : 25 - 36
  • [6] Mirabegron versus Antimuscarinics in the Treatment of Overactive Bladder: The Final Answer?
    Marcelissen, Tom A. T.
    Van Koeveringe, Gommert A.
    EUROPEAN UROLOGY, 2018, 74 (03) : 334 - 335
  • [7] Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada
    Wagg, Adrian
    Franks, Billy
    Ramos, Barbara
    Berner, Todd
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2015, 9 (9-10): : 343 - 350
  • [8] PERSISTENCE AND ADHERENCE WITH MIRABEGRON, A NEW BETA-3 RECEPTOR AGONIST, VERSUS ANTIMUSCARINICS IN OVERACTIVE BLADDER: EARLY EXPERIENCE IN CANADA
    Wagg, A.
    Franks, B.
    Ramos, B.
    Berner, T.
    VALUE IN HEALTH, 2014, 17 (07) : A471 - A471
  • [9] Comparative safety of antimuscarinics versus mirabegron for overactive bladder in Parkinson disease
    Abraham, Danielle S.
    Nguyen, Thanh Phuong Pham
    Newcomb, Craig W.
    Gray, Shelly L.
    Hennessy, Sean
    Leonard, Charles E.
    Liu, Qing
    Weintraub, Daniel
    Willis, Allison W.
    PARKINSONISM & RELATED DISORDERS, 2023, 115
  • [10] Persistence With Mirabegron Versus Tolterodine in Patients With Overactive Bladder
    Nitti, Victor W.
    Rovner, Eric S.
    Franks, Billy
    Muma, Gilbert N.
    Berner, Todd
    Fan, Alan
    Ng, Daniel B.
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2016, 8 (02)
12345